TY - JOUR AU - Coronado, Pluvio AU - de Santiago-López, Javier AU - de Santiago-García, Javier AU - Méndez, Ramiro AU - Fasero, Maria AU - Herraiz, Miguel PY - 2021/02/15 Y2 - 2024/03/29 TI - Tumoral volume measured preoperatively by magnetic resonance imaging is related to survival in endometrial cancer JF - Radiology and Oncology JA - Radiol Oncol VL - 55 IS - 1 SE - Radiology DO - UR - https://www.radioloncol.com/index.php/ro/article/view/3465 SP - 35-41 AB - <p><strong>ABSTRACT</strong></p><p><strong>Objective</strong>: To determine if the tumor volume measured by magnetic resonance image (MRI-TV) is associated with survival in endometrial cancer and lymph nodes metastases (LN+).</p><p><strong>Material and Methods</strong>: 341 women with EC and preoperative MRI were evaluated from 2008 to 2018. The MRI-TV was calculated using the ellipsoid formula measuring three perpendicular tumor diameters. Tumor myometrial invasion was also analyzed. Data from patient’s records was retrieved.&nbsp;</p><p><strong>Results</strong>: Higher MRI-TV was associated with an age ≥65y, non-endometrioid tumors, grade-3, deep-myometrial invasion, LN+, and advanced FIGO stage. There were 37 patients with LN+ (8.8%); non-endometrioid tumors, deep-myometrial invasion, grade-3, and MRI-TV ≥ 10 cm<sup>3</sup> were the factors associated with LN+. Using a COR curve, the MRI-TV cut-off for survival was 10 cm<sup>3 </sup>(area under curve = 0.70; 95%CI: 0.61-0.73). 5y disease-free (DFS) and overall survival (OS) was significantly lower in MRI-TV&nbsp;≥&nbsp;10&nbsp;cm<sup>3</sup> (69.3% vs 84.5%, and 75.4% vs 96.1% respectively). MRI-TV was considered an independent factor of DSF (HR: 2.20, 95%CI:1.09-4.45, <em>p</em>=0.029) and OS (HR: 3.88, 95%CI: 1.34-11.24, <em>p</em>&nbsp;=&nbsp;0.012) in multivariant analysis.</p><p><strong>Conclusion</strong>: MRV-TV is associated with LN+, and MRI-TV&nbsp;≥&nbsp;10&nbsp;cm<sup>3</sup> is an independent prognostic factor of lower DFS and OS. The MRI-TV can be ancillary information to plan the surgery strategy and predict the adjuvant treatment in women with endometrial cancer.</p> ER -